Experimental drug offers hope for lewy body dementia patients in extended access program
NCT ID NCT06961760
Summary
This program provided the experimental drug CT1812 to people with mild-to-moderate Lewy body dementia for up to one year. The main goal was to gather more information about the drug's long-term safety and whether it helps control symptoms of this progressive brain disease. Participants took the drug daily and attended regular clinic visits for assessments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner Sun Health Research Institute
Sun City, Arizona, 85351, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Ohio State University Wexner Medical Center (OSUWMC)
Columbus, Ohio, 43210, United States
-
Stanford Neuroscience Heath Center
Palo Alto, California, 94304, United States
-
Summit Headlands LLC
Portland, Oregon, 97210, United States
-
University of Colorado Denver - Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Miami - Department of Neurology
Boca Raton, Florida, 33433, United States
Conditions
Explore the condition pages connected to this study.